NY Judge Tosses $6.4B BMS Investor Action For Good
By Nadia Dreid · March 1, 2024, 9:29 PM EST
Celgene Corp. investors could not convince a New York federal judge that Bristol-Myers Squibb Co. was intentionally trying to flout securities law by delaying the U.S. Food and Drug Administration's approval...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login